ClinicalTrials.gg
CompletedNCT01895205PP-02Updated Aug 19, 2015

Treatment of Women After Severe Postpartum Haemorrhage

A Phase 3 interventional study of Iron isomaltoside 1000 and Red blood cell transfusion in Severe Postpartum Haemorrhage, sponsored by Pharmacosmos A/S. Completed at 1 site in Denmark. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-19.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The primary purpose of this study is to get explorative information about IV high single dose infusion of iron isomaltoside 1000 compared to RBC transfusion in the treatment of severe PP-IDA evaluated as physical fatigue

02

Conditions studied

  • Severe Postpartum Haemorrhage

Browse trials for

03

In context

Postpartum Hemorrhage

469 studies on the registry are indexed under Postpartum Hemorrhage; 75 are open to participants now.

This study's enrollment of 13 is below the median of 148 across 360 interventional studies indexed under Postpartum Hemorrhage.

Browse Postpartum Hemorrhage studies →

Lead sponsor

Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. PPH > 1000 mL
  2. ≥ 5.5 and ≤ 8.0 g/dL (≥ 3.5 and ≤ 5.0 mmol/L)
  3. Willingness to participate and signed the form

Exclusion criteria

Exclusion Criteria:

  1. Women aged \< 18 years
  2. Multiple births
  3. Peripartum RBC transfusion
  4. Known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
  5. Known to parenteral iron or any in the drug products
  6. Women with a history of active asthma within the last 5 years or a history of multiple allergies
  7. Known decompensated liver cirrhosis and active hepatitis
  8. Women with HELLP (Haemolysis Elevated Liver enzymes Low count) syndrome (defined according to "Dansk Selskab for Obstetrik og Gynækologi guidelines")
  9. Active acute infection assessed by clinical judgement
  10. Rheumatoid arthritis with symptoms or signs of active joint inflammation
  11. History of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia (known haematologic disorder other than iron deficiency)
  12. Not able to read, speak and understand the Danish language
  13. Participation in any other clinical study where the study drug has not passed 5 half-lives prior to the baseline
  14. Any other medical condition that, in the opinion of Investigator, may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from being in the study. For example, a , uncontrolled hypertension, unstable ischaemic heart disease or uncontrolled diabetes mellitus
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Iron isomaltoside 1000

    A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.

    Drug: Iron isomaltoside 1000

  • Active comparator
    Red blood cell transfusion

    Allogenic RBC transfusion is dosed to trigger Hb: * Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC * Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC

    Drug: Red blood cell transfusion

Interventions

06

What researchers measure

Primary outcomes

  1. Physical Fatigue

    Time frame: From exposure to 12 weeks post-exposure

Secondary outcomes

  1. Change in Hb concentration

    Time frame: From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12

  2. Change in p-ferritin

    Time frame: From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12

  3. Fatigue symptoms

    Time frame: from baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12

  4. Postpartum depression

    Time frame: From week 1 to 3, 8 and 12

  5. Breastfeeding

    Time frame: From exposure to 12 weeks post-exposure

  6. Number of adverse drug reactions (ADRs)

    Time frame: From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12

  7. Change in p-iron

    Time frame: From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12

  8. Change in p-transferrin

    Time frame: From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12

  9. Change in transferrin saturation (TSAT)

    Time frame: From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12

  10. Change in reticulocyte count

    Time frame: From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12

  11. Change mean reticulocyte haemoglobin content (CHr)

    Time frame: From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12

Other outcomes

  1. Change in anaemia symptoms

    Time frame: From Baseline to week 12

  2. Change in gastrointestinal symptoms

    Time frame: From Baseline to week 12

07

Study locations

1 site
  • Copenhagen, Denmark
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jul 10, 2013
Start
Jun 2013
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Aug 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01895205
Lead sponsor
Pharmacosmos A/S
Collaborators
BioStata
Responsible party
Sponsor
First posted
Jul 10, 2013
Start date
Jun 2013
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Aug 19, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion